The Latest Updates from ReSPECT Clinical Trials
Recognizing Rare Disease Day
Today, Plus Therapeutics joins the global community in recognizing Rare Disease Day, an annual moment dedicated to raising awareness and advancing efforts for the more than 300 million people worldwide living with a rare disease. Rare Disease Day serves as a powerful...
Rethinking Radiation Therapy: A Targeted Approach for Hard‑to‑Treat Cancers
Radiation therapy has been a cornerstone of cancer treatment for more than a century. Its ability to damage cancer cells and control tumor growth has made it one of the most widely used and effective therapeutic modalities in oncology. Yet despite its long history and...
Plus Therapeutics Announces Approval of New AMA Category III CPT® Code Supporting Use of Convection‑Enhanced Delivery with REYOBIQ™
Plus Therapeutics announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category III CPT code to track the utilization of convection‑enhanced delivery (CED) when used in the administration of REYOBIQ™ for patients with recurrent...
As radioligand therapies (RLTs) and theranostics continue to gain momentum across biopharma, the industry is entering a new era—one marked by tremendous opportunity, along with unique regulatory, manufacturing, and reimbursement challenges. In a recent article for...
Precision Medicine and the Next Wave of Innovation in CNS Cancers
Pharma’s Almanac recently asked a group of biopharma leaders an important question: What emerging technologies or scientific breakthroughs will most reshape biopharma over the next decade? Among those featured was Marc Hedrick, MD, President and CEO of Plus...
Advancing Innovation in Brain Cancer Research: Highlights from the SU2C Innovation Summit
ReSPECT Clinical Trial's Dr. Brenner recently participated in another Stand Up To Cancer® (SU2C) Innovation Summit, focused on advancing novel approaches for the detection and treatment of gliomas, a complex and aggressive form of brain cancer. The summit convened...
World Cancer Day 2026
On World Cancer Day, Plus Therapeutics proudly joins the global oncology community to raise awareness of cancer and reaffirm a shared commitment to improving access to high‑quality, equitable care for patients worldwide. Established in 2000 by the Union for...
Advancing Innovation in CNS Cancer Care on the Empowered Patient Podcast
Marc Hedrick, President & CEO of Plus Therapeutics, recently joined Karen Jagoda on the Empowered Patient Podcast for an in‑depth discussion on the company’s mission to advance care for patients with central nervous system (CNS) cancers. During the interview, Dr....
Plus Therapeutics and CNSide Diagnostics to Participate in the Inaugural Brain & Spine Metastases Conference
Plus Therapeutics and CNSide Diagnostics are pleased to participate in the Inaugural Brain & Spine Metastases Conference, taking place this Thursday in Miami, Florida. The event brings together leading clinicians, researchers, and innovators focused on advancing...
The Leptomeningeal Metastases Clinical Education Poster
Plus Therapeutics is proud to collaborate with CNSide Diagnostics and the Leptomeningeal Cancer Foundation on the development of a new educational resource designed to support individuals affected by leptomeningeal metastases (LM), as well as their caregivers and...
Plus Therapeutics Completes FDA Type B Meeting on REYOBIQ™ Pivotal Trial Strategy in Leptomeningeal Metastases
Plus Therapeutics is pleased to announce the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss next steps in the clinical development of REYOBIQ™ for the treatment of leptomeningeal metastases (LM). This meeting...
AJMC: Leptomeningeal Metastases Data at SABCS 2025
Expert Insights: Dr. Andrew Brenner on the Path Forward In a recent video interview with Sabrina McCrear of AJMC – The American Journal of Managed Care, Andrew Brenner, MD, PhD, provided a deeper look into the significance of the SABCS presentations. Dr. Brenner...
Targeted Radiotherapeutics: A New Generation of Precision Cancer Treatment
What Are Targeted Radiotherapeutics? Targeted radiotherapeutics are designed to deliver radiation from within the body, directly to tumor sites, using advanced targeting mechanisms that guide radioactive payloads to cancer cells with high precision. Unlike traditional...
ReSPECT-LM Clinical Trial Highlights Phase 1 Results at SABCS 2025
At the 2025 San Antonio Breast Cancer Symposium (SABCS), Plus Therapeutics and its clinical partners shared important progress in the fight against leptomeningeal metastases (LM) with the presentation of Phase 1 dose escalation results from the ReSPECT-LM clinical...
Three Positive Clinical Data Updates at WFNOS / SNO 2025 Annual Meeting
Plus Therapeutics is pleased to announce the presentation of three positive clinical data updates at the World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) 2025 Annual Meeting. These new findings advance the Company’s growing body...
Progress, Potential, and Possibilities Podcast
Plus Therapeutics’ growing momentum in central nervous system (CNS) oncology was recently spotlighted when President & CEO Marc Hedrick, MD, joined host Ira S. Pastor on the Progress, Potential, and Possibilities podcast. The in-depth discussion provides a clear,...
Poster Spotlight (with Oral) Presentation at SABCS 2025
Plus Therapeutics is pleased to announce that its abstract has been accepted for a Poster Spotlight with Oral Presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025), taking place December 9–12, 2025, in San Antonio, Texas. This recognition...
Game On Glio Podcast
Innovations in brain cancer treatment continue to advance, fueled by the dedication of leading clinicians and researchers across the globe. In the latest episode of the Game On Glio podcast, Toral Patel, MD (UT Southwestern Medical Center) and Andrew Brenner, MD, PhD...
Plus Therapeutics Completes FDA Type B Meeting to Advance REYOBIQ™ Development for LM
Plus Therapeutics announced that it has successfully completed a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s clinical development plans for REYOBIQ™, its targeted radiotherapeutic for leptomeningeal metastases (LM). The...
WFNOS / SNO 2025 Annual Meeting
Plus Therapeutics is pleased to announce that the Company will present three new clinical data updates at this year’s World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) Annual Meeting. The conference, one of the largest global...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 Recognizing Rare Disease Day
- 1.2 Rethinking Radiation Therapy: A Targeted Approach for Hard‑to‑Treat Cancers
- 1.3 Plus Therapeutics Announces Approval of New AMA Category III CPT® Code Supporting Use of Convection‑Enhanced Delivery with REYOBIQ™
- 1.4 Navigating the Future of Radiopharmaceuticals
- 1.5 Precision Medicine and the Next Wave of Innovation in CNS Cancers
- 1.6 Advancing Innovation in Brain Cancer Research: Highlights from the SU2C Innovation Summit
- 1.7 World Cancer Day 2026
- 1.8 Advancing Innovation in CNS Cancer Care on the Empowered Patient Podcast
- 1.9 Plus Therapeutics and CNSide Diagnostics to Participate in the Inaugural Brain & Spine Metastases Conference
- 1.10 The Leptomeningeal Metastases Clinical Education Poster
- 1.11 Plus Therapeutics Completes FDA Type B Meeting on REYOBIQ™ Pivotal Trial Strategy in Leptomeningeal Metastases
- 1.12 AJMC: Leptomeningeal Metastases Data at SABCS 2025
- 1.13 Targeted Radiotherapeutics: A New Generation of Precision Cancer Treatment
- 1.14 ReSPECT-LM Clinical Trial Highlights Phase 1 Results at SABCS 2025
- 1.15 Three Positive Clinical Data Updates at WFNOS / SNO 2025 Annual Meeting
- 1.16 Progress, Potential, and Possibilities Podcast
- 1.17 Poster Spotlight (with Oral) Presentation at SABCS 2025
- 1.18 Game On Glio Podcast
- 1.19 Plus Therapeutics Completes FDA Type B Meeting to Advance REYOBIQ™ Development for LM
- 1.20 WFNOS / SNO 2025 Annual Meeting